Conferences - Results from #320

Viewing 321-340 of 11879 articles

ESMO 2024: Real World Efficacy of 1st Line Nivolumab plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)

ESMO 2024: How to Manage Patients with Durable Response on Systemic Therapy? Optimal Therapy Duration and Role De-Escalation?

ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial

ESMO 2024: CaboPoint: Final Results from a Phase 2 Study of Cabozantinib After Checkpoint Inhibitor Combinations in Patients with Advanced Renal Cell Carcinoma

ESMO 2024: Building on Standard Therapies: Novel Agents and Promising Combinations in Urothelial and Renal Cell Carcinoma

ESMO 2024: Circulating Versus Tissue-Based Biomarkers

ESMO 2024: Opevesostat (MK-5684/ODM-208), an Oral CYP11A1 Inhibitor, in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated CYPIDES Phase 2 Results

ESMO 2024: What Is the Role of Rechallenge with the Same Class of Agents in Advanced Disease?

ESMO 2024: SOGUG-NEOWIN: Erdafitinib Monotherapy and Erdafitinib and Cetrelimab as Neoadjuvant Treatment in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer and FGFR Gene Alterations

ESMO 2024: Novel Therapeutic Approaches for ARPI-resistant Disease

ESMO 2024: The Role of Urologist in Bladder Preservation Strategies

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

ESMO 2024: Clinical responders: Option of Chemoradiation?

ESMO 2024: Biomarkers and Prediction of Clinical Complete Response in Bladder Cancer

ESMO 2024: Will Theranostics Become Standard of Care?

ESMO 2024: Could Optimal Systemic Therapy Be Adequate Without Locoregional Therapy?

ESMO 2024: Invited Discussant: Optimizing Post-IO Therapy in Clear Cell RCC and Expanding Options for Non-Clear Cell RCC

ESMO 2024: Invited Discussant: Moving the Needle: Novel Targets and Refined Approaches in Genitourinary Cancers

ESMO 2024: NKT2152, a Novel Oral HIF-2α Inhibitor, in Participants with Previously Treated Advanced Clear Cell RCC: Preliminary Results of a Phase 1/2 Study

ESMO 2024: BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

12
13
14
15
16
17
18
19
20
21